Similar articles

• Is there added value to adding ARB to ACE inhibitors in the management of CKD?

  Cohen DL, Townsend RR. Cohen DL, et al. J Am Soc Nephrol. 2009 Aug;20(8):1666-8. doi: 10.1681/ASN.2008040381. Epub 2008 Sep 5. J Am Soc Nephrol. 2009. PMID: 18776118
• Angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers after renal transplantation.

  Morath C, Schmied B, Mehrabi A, Weitz J, Schmidt J, Werner J, Buchler MW, Morcos M, Nawroth PP, Schwenger V, Doehler B, Opelz G, Zeier M. Morath C, et al. Clin Transplant. 2009 Dec;23 Suppl 21:33-6. doi: 10.1111/j.1399-0012.2009.01107.x. Clin Transplant. 2009. PMID: 19930314 Review.
• Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.

  Toto R, Palmer BF. Toto R, et al. Am J Nephrol. 2008;28(3):372-80. doi: 10.1159/000112269. Epub 2007 Dec 12. Am J Nephrol. 2008. PMID: 18073461 Review.
• How should renin-angiotensin system blockade be applied in chronic kidney disease for optimal renal protection?

  Zhang X, Hou FF. Zhang X, et al. Chin Med J (Engl). 2007 Feb 5;120(3):243-5. Chin Med J (Engl). 2007. PMID: 17355830 No abstract available.
• Are two better than one? Angiotensin-converting enzyme inhibitors plus angiotensin receptor blockers for reducing blood pressure and proteinuria in kidney disease.

  Linas SL. Linas SL. Clin J Am Soc Nephrol. 2008 Jan;3 Suppl 1(Suppl 1):S17-23. doi: 10.2215/CJN.03270807. Clin J Am Soc Nephrol. 2008. PMID: 18178792 Free PMC article. Review.